Days after the FDA approved
J&J’s COVID vaccine for emergency use, the company announced plans
to test the vaccine on newborns, despite the vaccine’s risks and strong
evidence that COVID poses virtually no risk to healthy children.
By
Megan Redshaw
On Friday, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization for Johnson & Johnson’s (J&J) COVID vaccine, paving the way for the one-shot vaccine to be administered beginning this week.
The Centers for Disease Control and Prevention (CDC) also recommended the vaccine for people 18 and older. On Sunday, J&J revealed plans
to test its one-shot vaccine on infants, including newborns, pregnant
women and the immunocompromised. The expanded clinical trials were laid
out in the company’s application for emergency use approval and in briefing materials provided to the FDA and discussed briefly during the meeting.
According to the New York Times, the plan for expanded clinical trials met the approval of Dr. Ofer Levy, director of the Precision Vaccines Program at Harvard’s Boston Children’s Hospital and a member of the FDA’s advisory committee that reviewed the company’s vaccine data.
Read more
Be the first to comment.
Blogger's note:
subterrnews.blogspot.com does not send cookies, or collect any information on
those using the blog. However, the blogspot is on google, and google may
collect information, and send cookies. Many of the links that we
connect to do not send out cookies or collect information, but some do.
You are keying in to this blog, and you have agreed to this.
The views expressed in the articles
do not necessarily represent the opinions of this blog. They are the views, and opinions of the
author(s) of the article.
0 comments:
Post a Comment